DLBCL
Conditions
Keywords
BTK inhibitor, DLBCL, R-GemOx
Brief summary
This is a multicenter, open-label phase Ib study, evaluating the safety, tolerability, preliminary efficacy and PK characteristics of Rocbrutinib (LP-168) combined with R-GemOx in patients with R/R non-GCB DLBCL. Study includes dose escalation part and dose expansion part. In the dose escalation part, a classic "3+3" design will be used to assess the safety of each specified dose combination. Upon completion of a predefined escalation part, the decision on whether to proceed to the dose expansion part will be based on the safety, PK, and efficacy data of the combination regimen.
Interventions
DRUGRocbrutinib
Patients will receive Rocbrutinib until disease progression or unacceptable toxicity
DRUGR-GemOx
Patients will receive 6 cycles every 21 days of R-GemOx. Rituximab 375mg/m2 i.v. on day 1 of every cycle. GemOx (gemcitabine 1000mg/m2 plus oxaliplatin 100mg/m2) i.v. on day 2 of each cycle.
Sponsors
Guangzhou Lupeng Pharmaceutical Company LTD.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with relapsed or refractory non-GCB DLBCL. * Have at least one measurable lesion according to the Lugano Response Criteria 2014. * ECOG performance status 0-2 (0-1 for dose escalation part). * Life expectancy ≥ 12 weeks. * Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function. * No plan for autologous/allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor T-cell (CAR-T) therapy. * Toxicities from prior anti-tumor therapy have recovered to Grade ≤1 according to NCI CTCAE v5.0. * All male subjects and female subjects of childbearing potential must strictly use medically approved contraception throughout the entire study period. All male subjects must also avoid sperm donation during the above period. For women of childbearing potential, the result of serum pregnancy test must be obtained. Women must be non-lactating * Subjects must provide adequate tissue and blood samples for exploratory study. Participation is voluntary, requiring signed informed consent and compliance with the treatment regimen and visit schedule.
Exclusion criteria
* Intolerance to Rocbrutinib or any drug in the combination regimen. * Prior treatment with a BTK-targeted therapy; prior treatment with R-GemOx. * DLBCL transformed from an indolent lymphoma; diagnosis of high-grade or double-hit DLBCL. * Chemotherapy, biologic therapy (except CAR-T), immunotherapy or major surgery within 4 weeks of the first dose of study treatment. * Small molecule targeted therapy within 4 weeks or within 5 half-lives (whichever is shorter) of the first dose of study treatment. * Herbal or proprietary Chinese medicines with antitumor activity or radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment. * History of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) or other organ transplantation, or autologous HSCT (auto-HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy within 90 days of the first dose of study treatment. * Current corticosteroid therapy at a dose \>20 mg/day prednisone equivalent. The prednisone-equivalent dose must have been stable for at least 4 weeks before Cycle 1 Day 1. * Unable to discontinue prohibited medications during the study period (strong or moderate CYP3A inhibitors or inducers, P-gp inhibitors, OATP1B3-sensitive substrates, warfarin or other vitamin K antagonists). * Known or suspected CNS involvement by lymphoma. * Presence of peripheral neuropathy \> Grade 1. * Any severe and/or uncontrolled systemic disease, or condition affecting drug swallowing or absorption, that in the investigator's judgment makes the subject unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLTs | At the end of Cycle 1 (the length of cycle 1 is 21 days) | Dose-Limiting Toxicities |
| MTD | At the end of Cycle 1 (the length of cycle 1 is 21 days) | Maximum Tolerated Dose |
| Adverse events as assessed by CTCAE v5.0 | From the first administration to 28 days after the last administration | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Up to approximately two years | Overall Response Rate |
| TTR | Up to approximately two years | Time to Response |
| DoR | Up to approximately two years | Duration of Response |
| PFS | Up to approximately two years | Progression-free Survival |
| OS | Up to approximately two years | Overall Survival |
| Cmax | From 1 hour prior to administration to 24 hours post-dose | Maximum Plasma Concentration |
| Tmax | From 1 hour prior to administration to 24 hours post-dose | Time to Maximum Plasma Concentration |
| AUC0-t | From 1 hour prior to administration to 24 hours post-dose | Area Under the Plasma Concentration-Time Curve from Time Zero to Time t |
| t1/2 | From 1 hour prior to administration to 24 hours post-dose | Half-life |
Countries
China
Contacts
CONTACTQingqing Cai
CONTACTRong Tao
Outcome results
None listed